Regulatory Analysis · 2026
FDA Peptide Compounding Status (2026): 503A Category 2 & PCAC Reality Check
Executive Brief
Despite widespread online rumors of an immediate “peptide unbanning,” investigational peptides including BPC-157, TB-500, MOTS-c, Epitalon, and Retatrutide remain unapproved compounds that are not cleared for human compounding by the U.S. Food and Drug Administration. This guide explains Section 503A Category 2 bulk drug substance rules, Pharmacy Compounding Advisory Committee (PCAC) deliberations versus binding rulemaking, and current regulatory boundaries in 2026.
FDA 503A Category 2 Analysis
How FDA Section 503A Bulk Drug Substance Categories Work
Under Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act, state-licensed compounding pharmacies may only compound medications using bulk drug substances (active pharmaceutical ingredients) that meet one of three statutory criteria: (1) the substance is the subject of an applicable USP or NF monograph, (2) it is a component of an FDA-approved drug product, or (3) it appears on the FDA's final 503A Bulks List developed through formal notice-and-comment rulemaking.
While developing the final 503A Bulks List, the FDA established an interim enforcement policy dividing nominated bulk substances into three categories:
- Category 1: Bulk substances currently under evaluation that may be eligible for interim compounding while the FDA completes formal rulemaking.
- Category 2: Bulk substances that the FDA has identified as raising significant safety risks (such as immunogenicity, peptide aggregation impurities, or lack of human safety data). Pharmacies are prohibited from compounding Category 2 substances.
- Category 3: Nominated substances submitted without sufficient supporting scientific data for the FDA to evaluate.
In late 2023, the FDA updated its interim Category 2 list to include numerous widely discussed peptides, effectively halting their preparation by U.S. 503A and 503B compounding pharmacies.
Peptides Subject to FDA Category 2 & Unapproved Status
The compounds most frequently discussed in peptide research communities that have been placed on Category 2 or flagged as unapproved investigational substances include:
- BPC-157 (Body Protection Compound-157 — unapproved gastric pentadecapeptide; cited by FDA for lack of human clinical safety data and immunogenicity risk)
- TB-500 / Thymosin Beta-4 (synthetic actin-sequestering peptide fragment; unapproved for human compounding)
- CJC-1295 & Ipamorelin (growth hormone secretagogues flagged for cardiovascular and endocrine safety questions in compounded parenteral forms)
- AOD-9604, Melanotan II, Selank, Semax, DSIP, Epitalon, MOTS-c, KPV, LL-37, and PEG-MGF (all remain unapproved investigational compounds not cleared for human therapeutic compounding)
- Retatrutide (LY3437943) (an investigational Phase 3 triple agonist owned by Eli Lilly; not FDA-approved and explicitly targeted by FDA warning letters against unauthorized compounding or research-chemical sales for human use)
Note on GHK-Cu: while topical cosmetic products containing copper tripeptide-1 are marketed commercially as cosmetics, injectable GHK-Cu remains prohibited from 503A human compounding.
PCAC Deliberations vs. Binding Rulemaking
PCAC Deliberations vs. Binding FDA Rules: Separating Policy Signals from Law
Throughout 2025 and 2026, public statements by federal health officials, lawsuits by compounding coalitions, and nominations before the Pharmacy Compounding Advisory Committee (PCAC) generated intense speculation that 12 or more Category 2 peptides were being immediately restored to compounding pharmacies.
In regulatory practice, it is critical to distinguish three separate processes:
- 1. Public Policy Statements & Petitions: Statements by HHS leadership or stakeholder petitions requesting that the FDA re-evaluate Category 2 listings do not automatically alter the legal status of a bulk drug substance.
- 2. PCAC Advisory Meetings: The Pharmacy Compounding Advisory Committee reviews scientific dossiers and votes on non-binding recommendations to the FDA Commissioner. Historically, PCAC has voted against adding most investigational peptides (such as BPC-157, Thymosin Alpha-1, and AOD-9604) to the 503A Bulks List due to limited human toxicology and pharmacokinetic data.
- 3. Binding Federal Register Rulemaking / Guidance Updates: A compound is only legally cleared for 503A compounding if the FDA formally moves it to Category 1 in its published interim guidance or adds it to the positive 503A Bulks List in the Code of Federal Regulations (21 CFR 216.23) following notice-and-comment rulemaking.
Furthermore, biological products (Generally proteins >40 amino acids, and certain regulated peptide classes) and commercially available FDA-approved GLP-1 drugs (such as semaglutide and tirzepatide following resolution of drug shortages) are subject to additional statutory compounding restrictions under Sections 503A and 503B.
Related Foundational Guides
Understanding regulatory classifications is essential before reading preclinical or clinical peptide literature. BPC-157, TB-500, MOTS-c, and Epitalon remain unapproved investigational substances, not FDA-approved medications. If you are new to peptide science and evidence grading, start with our Peptide Therapy 101 and Peptide Safety & Contamination Risks guides.
Frequently Asked Questions
Are BPC-157, TB-500, or Retatrutide FDA-approved in 2026?
No. BPC-157, TB-500, Epitalon, MOTS-c, and Retatrutide are unapproved investigational compounds. None of them have been approved by the FDA for any medical indication, nor are they cleared for human compounding under Section 503A.
What is the difference between a PCAC review and FDA approval?
Full FDA drug approval requires an Investigational New Drug (IND) application and Phase 1–3 human clinical trials culminating in an approved New Drug Application (NDA). A Pharmacy Compounding Advisory Committee (PCAC) review only evaluates whether an unapproved bulk substance may be compounded by 503A pharmacies, and PCAC votes are advisory rather than binding law.
Why did the FDA place peptides like BPC-157 in Category 2?
The FDA cited the absence of adequate human clinical safety and toxicology data, potential immunogenicity (anti-drug antibodies), and peptide-related impurities or aggregates that can form during synthesis and compounding.
Can compounding pharmacies compound semaglutide or tirzepatide in 2026?
Under Sections 503A and 503B, pharmacies cannot compound 'essentially a copy' of an commercially available FDA-approved drug unless that drug is actively listed on the FDA Drug Shortage List. Following FDA determinations that tirzepatide and semaglutide injection shortages resolved, routine compounding of copies faces strict federal enforcement.
Are Category 2 peptides banned in competitive sports?
Yes. Independent of FDA compounding rules, BPC-157, TB-500, CJC-1295, Ipamorelin, MOTS-c, and all unapproved peptides are prohibited at all times for tested athletes under the World Anti-Doping Agency (WADA) S0 (Non-Approved Substances) and S2 (Peptide Hormones and Growth Factors) lists.
Regulatory & Medical Disclaimer
All content on this page is provided for informational and educational research purposes only based on public regulatory filings, preliminary clinical data, and anecdotal reports. Nothing here constitutes legal or medical advice. Always consult a licensed physician and qualified legal counsel regarding regulatory compliance in your jurisdiction.
Related Guides
What Is a Peptide?
A plain-English introduction to peptides — how they differ from proteins, hormones, and drugs, and why researchers use them.
Peptide Therapy 101
What peptide therapy is, how it works, who benefits most, and what your first cycle looks like.
Peptide Therapy Safety & Risks
An honest look at safety profiles, contamination risks, and what to watch for when sourcing peptides.
Side Effects: The Honest Truth
Real side effects reported by the community — what's common, what's rare, and what's overblown.